Zacks Investment Research upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $91.00 price objective on the specialty pharmaceutical company’s stock.
According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
Several other equities research analysts also recently commented on ANIP. ValuEngine upgraded Xylem from a hold rating to a buy rating in a report on Friday, June 21st. TheStreet upgraded TerraForm Power from a c rating to a b- rating in a report on Tuesday, March 19th. Canaccord Genuity downgraded Magellan Aerospace from a buy rating to a hold rating and dropped their price objective for the stock from C$21.00 to C$20.00 in a report on Monday, May 13th. BidaskClub downgraded Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, July 11th. Finally, Cantor Fitzgerald restated a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $88.00.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.05 by $0.25. The business had revenue of $52.90 million for the quarter, compared to the consensus estimate of $50.57 million. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The company’s revenue was up 13.8% on a year-over-year basis. During the same period last year, the business posted $1.32 EPS. Equities research analysts expect that ANI Pharmaceuticals will post 5.57 EPS for the current year.
In other news, SVP Robert W. Schrepfer sold 2,409 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $71.13, for a total value of $171,352.17. Following the completion of the transaction, the senior vice president now owns 55,927 shares in the company, valued at approximately $3,978,087.51. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Arthur Przybyl sold 30,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total value of $2,102,100.00. Following the completion of the transaction, the insider now owns 222,994 shares of the company’s stock, valued at approximately $15,625,189.58. The disclosure for this sale can be found here. Insiders have sold a total of 50,911 shares of company stock worth $3,585,114 over the last 90 days. 24.70% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Financial Gravity Wealth Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $54,000. Quantamental Technologies LLC grew its position in shares of ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 542 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of ANI Pharmaceuticals by 55,466.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 1,664 shares in the last quarter. Truvestments Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $140,000. Finally, BerganKDV Wealth Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $141,000. Institutional investors own 63.95% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Article: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.